Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic

American Journal of Health-System Pharmacy

Volumn 71, Issue 11, 2014, Pages 960-965

  Wong, Siu Fun ^a,b   Bounthavong, Mark ^c   Nguyen, Cham ^d   Bechtoldt, Kezia ^e   Hernandez, Elvin ^b  

^a CHAPMAN UNIVERSITY   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d ST JOSEPH HOSPITAL   (United States)

^e LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; ERLOTINIB; EVEROLIMUS; HYDROXYUREA; LAPATINIB; LENALIDOMIDE; NERATINIB; TAMOXIFEN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC PAIN; CLINICAL ARTICLE; COHORT ANALYSIS; COST CONTROL; DEPRESSION; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERTENSION; MALE; MEDICATION COMPLIANCE; MEDICATION ERROR; MEDICATION THERAPY MANAGEMENT; OBSERVATIONAL STUDY; ORAL CHEMOTHERAPY MANAGEMENT; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; RETROSPECTIVE STUDY; SELF REPORT; UNSPECIFIED SIDE EFFECT; CANCER STAGING; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; FEMALE; HUMANS; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84907188955     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130278     Document Type: Article

References (10)

1. Increased use of oral chemotherapy drugs spurs increased attention to patient compliance. J Oncol Pract. 2008; 4:175-7.
2. Sharma S, Saltz LB. Oral chemotherapeutic agents for colorectal cancer. Oncologist. 2000; 5:99-107.
3. Weingart SN, Brown E, Bach PB et al. NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw. 2008; 6(suppl 3):S1-14.
4. Zung WW, Richard CB, Short MJ. Self-rating depression scale in an outpatient clinic. Further validation of the SDS. Arch Gen Psychiatry. 1965; 13:508-15.
5. Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Truven Health Analytics. Updated periodically.
6. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. Cancer. 2009; 59:56-66.
7. Lee AJ, Boro MS, Knapp KK et al. Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health-Syst Pharm. 2002; 59:2070-7.
8. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365:60-2.
9. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006; 71:1-9.
10. Partridge AH, Archer L, Kornblith AB et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010; 28:2418-22.